In the latest episode of "In the Interim…", Dr. Scott Berry and Dr. Mike Krams sit down with Dr. Husseini Manji, to explore the potential of platform trials in advancing precision medicine within psychiatry. Listen as we discuss how an adaptive platform trial could transform drug development, paving the way for breakthroughs in understanding and treating psychiatric disorders.
Key Highlights:
- Overview of the burden of serious mental illness and the pressing need for innovative treatment approaches.
- Discussion on precision psychiatry and the potential of a platform trial to address the heterogeneity of psychiatric disorders.
- Insights into the advantages of biomarker-based adaptive trials in improving drug development success rates.
- Examination of potential sponsorship models for platform trials, emphasizing patient and industry collaboration.
Quotes:
- "Mental illnesses represent a significant global challenge with a staggering unmet need." – Husseini Manji
- "There's a real excitement about precision psychiatry—moving away from a one-size-fits-all approach." – Husseini Manji
- "The patient perspective is crucial for driving significant advances in psychiatric treatment." – Mike Krams
- "We believe that precision medicine biomarker-based adaptive trials could be game-changing in this space." – Husseini Manji
